Structure-based prediction of BRAF mutation classes using machine-learning approaches.

Fanny S Krebs, Christian Britschgi, Sylvain Pradervand, Rita Achermann, Petros Tsantoulis, Simon Haefliger, Andreas Wicki, Olivier Michielin, Vincent Zoete

Journal: Scientific reports 2022;12(1):12528

PMID: 35869122

Abstract

The BRAF kinase is attracting a lot of attention in oncology as alterations of its amino acid sequence can constitutively activate the MAP kinase signaling pathway, potentially contributing to the malignant transformation of the cell but at the same time rendering it sensitive to targeted therapy. Several pathologic BRAF variants were grouped in three different classes (I, II and III) based on their effects on the protein activity and pathway. Discerning the class of a BRAF mutation permits to adapt the treatment proposed to the patient. However, this information is lacking new and experimentally uncharacterized BRAF mutations detected in a patient biopsy. To overcome this issue, we developed a new in silico tool based on machine learning approaches to predict the potential class of a BRAF missense variant. As class I only involves missense mutations of Val600, we focused on the mutations of classes II and III, which are more diverse and challenging to predict. Using a logistic regression model and features including structural information, we were able to predict the classes of known mutations with an accuracy of 90%. This new and fast predictive tool will help oncologists to tackle potential pathogenic BRAF mutations and to propose the most appropriate treatment for their patients.

© 2022. The Author(s).

Address: Computer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, University of Lausanne, Epalinges, Switzerland.; Department of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland.; Center for Precision Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.; Department of Radiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Oncology, Hôpitaux Universitaires de Genève, University of Geneva, Geneva, Switzerland.; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Computer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, University of Lausanne, Epalinges, Switzerland. [email protected].; Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.